135 related articles for article (PubMed ID: 23531648)
41. The Self-administered Eczema Area and Severity Index in children with moderate to severe atopic dermatitis: better estimation of AD body surface area than severity.
van Velsen SG; Knol MJ; Haeck IM; Bruijnzeel-Koomen CA; Pasmans SG
Pediatr Dermatol; 2010; 27(5):470-5. PubMed ID: 20796235
[TBL] [Abstract][Full Text] [Related]
42. Serum squamous cell carcinoma antigen (SCCA)-2 correlates with clinical severity of pediatric atopic dermatitis in Ishigaki cohort.
Takeuchi S; Furusyo N; Ono J; Azuma Y; Takemura M; Esaki H; Yamamura K; Mitamura Y; Tsuji G; Kiyomatsu-Oda M; Hayashi J; Izuhara K; Furue M
J Dermatol Sci; 2019 Aug; 95(2):70-75. PubMed ID: 31378660
[TBL] [Abstract][Full Text] [Related]
43. Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis.
Furukawa H; Takahashi M; Nakamura K; Kaneko F
J Dermatol Sci; 2004 Dec; 36(3):165-72. PubMed ID: 15541638
[TBL] [Abstract][Full Text] [Related]
44. [THE BRIEF COMMENTARY ON GUIDELINES FOR THE MANAGEMENT OF ATOPIC DERMATITIS 2015 - FORCUSING ON THE BIOMARKER AND SKIN CARE].
Katoh N
Arerugi; 2017; 66(8):991-994. PubMed ID: 28904286
[No Abstract] [Full Text] [Related]
45. Incidence, serum IgE and TARC/CCL17 levels in atopic dermatitis associated with other allergic diseases: an update from the Ishigaki cohort.
Takeuchi S; Esaki H; Furusyo N; Hayashida S; Yamamura K; Tsuji G; Takemura M; Hayashi J; Furue M
Acta Derm Venereol; 2015 Apr; 95(4):480-4. PubMed ID: 25350554
[TBL] [Abstract][Full Text] [Related]
46. Different effect of oral cyclosporine therapy and oral antihistamine therapy on serum high-sensitivity C-reactive protein level and thymus and activation-regulated chemokine level in atopic dermatitis in older children and adulthood.
Ohtsuka T
Int J Dermatol; 2015 Jun; 54(6):648-55. PubMed ID: 25312097
[TBL] [Abstract][Full Text] [Related]
47. Reduction of serum thymus and activation-regulated chemokine after short-term intensive therapy may predict better prognosis of moderate to severe atopic dermatitis.
Saito R; Tanaka A; Hiragun T; Iwamoto K; Takahagi S; Takahashi M; Hide M
J Dermatol; 2019 Dec; 46(12):e486-e487. PubMed ID: 31376173
[No Abstract] [Full Text] [Related]
48. Significance of interleukin-16, macrophage-derived chemokine, eosinophil cationic protein and soluble E-selectin in reflecting disease activity of atopic dermatitis--from laboratory parameters to clinical scores.
Angelova-Fischer I; Hipler UC; Bauer A; Fluhr JW; Tsankov N; Fischer TW; Elsner P
Br J Dermatol; 2006 Jun; 154(6):1112-7. PubMed ID: 16704642
[TBL] [Abstract][Full Text] [Related]
49. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma.
Sauer M; Plütschow A; Jachimowicz RD; Kleefisch D; Reiners KS; Ponader S; Engert A; von Strandmann EP
Am J Hematol; 2013 Feb; 88(2):113-5. PubMed ID: 23225085
[TBL] [Abstract][Full Text] [Related]
50. Determination of thymus and activation-regulated chemokine (TARC)-contents in scales of atopic dermatitis.
Morita E; Hiragun T; Mihara S; Kaneko S; Matsuo H; Zhang Y; Dekio S
J Dermatol Sci; 2004 May; 34(3):237-40. PubMed ID: 15113595
[TBL] [Abstract][Full Text] [Related]
51. Nocturnal wrist movements are correlated with objective clinical scores and plasma chemokine levels in children with atopic dermatitis.
Hon KL; Lam MC; Leung TF; Kam WY; Lee KC; Li MC; Fok TF; Ng PC
Br J Dermatol; 2006 Apr; 154(4):629-35. PubMed ID: 16536804
[TBL] [Abstract][Full Text] [Related]
52. Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis.
Hashimoto S; Nakamura K; Oyama N; Kaneko F; Tsunemi Y; Saeki H; Tamaki K
J Dermatol Sci; 2006 Nov; 44(2):93-9. PubMed ID: 17008059
[TBL] [Abstract][Full Text] [Related]
53. TARC and MDC are produced by CD40 activated human B cells and are elevated in the sera of infantile atopic dermatitis patients.
Lin L; Nonoyama S; Oshiba A; Kabasawa Y; Mizutani S
J Med Dent Sci; 2003 Mar; 50(1):27-33. PubMed ID: 12715916
[TBL] [Abstract][Full Text] [Related]
54. Thymus- and activation-regulated chemokine (TARC/CCL17) induces a Th2-dominated inflammatory reaction on intradermal injection in mice.
Vestergaard C; Deleuran M; Gesser B; Larsen CG
Exp Dermatol; 2004 Apr; 13(4):265-71. PubMed ID: 15086343
[TBL] [Abstract][Full Text] [Related]
55. Serum mucosa-associated epithelial chemokine (MEC/CCL28) in atopic dermatitis: a specific marker for severity.
Ezzat MH; Sallam MA; Shaheen KY
Int J Dermatol; 2009 Aug; 48(8):822-9. PubMed ID: 19659860
[TBL] [Abstract][Full Text] [Related]
56. Serum thymus and activation-regulated chemokine (TARC/CCL17) levels reflect the disease activity in a patient with bullous pemphigoid.
Nin-Asai R; Muro Y; Sekiya A; Sugiura K; Akiyama M
J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):327-8. PubMed ID: 25201568
[No Abstract] [Full Text] [Related]
57. Thymus and Activation-regulated Chemokine as a Biomarker for IgG4-related Disease.
Umeda M; Origuchi T; Kawashiri SY; Koga T; Ichinose K; Furukawa K; Sato T; Tsuji S; Endo Y; Takatani A; Shimizu T; Fukui S; Iwamoto N; Igawa T; Tamai M; Nakamura H; Kawakami A
Sci Rep; 2020 Apr; 10(1):6010. PubMed ID: 32265499
[TBL] [Abstract][Full Text] [Related]
58. [BIOMARKER FOR ATOPIC DERMATITIS IN CHILDREN：FOCUSING ON TARC AND NOVEL SCCA2].
Fujisawa T
Arerugi; 2018; 67(8):981-986. PubMed ID: 30249957
[No Abstract] [Full Text] [Related]
59. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.
Bussmann C; Maintz L; Hart J; Allam JP; Vrtala S; Chen KW; Bieber T; Thomas WR; Valenta R; Zuberbier T; Sager A; Novak N
Clin Exp Allergy; 2007 Sep; 37(9):1277-85. PubMed ID: 17845407
[TBL] [Abstract][Full Text] [Related]
60. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
